Australia Markets closed

NeuroBo Pharmaceuticals, Inc. (NRBO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7000-0.0389 (-5.26%)
As of 01:13PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.86
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 363.8500
52-week low 30.5510
50-day moving average 30.7332
200-day moving average 37.0269

Share statistics

Avg vol (3-month) 3892.08k
Avg vol (10-day) 3222.25k
Shares outstanding 518.97M
Implied shares outstanding 6N/A
Float 86.44M
% held by insiders 165.92%
% held by institutions 12.81%
Shares short (12 Jan 2023) 4141.14k
Short ratio (12 Jan 2023) 40.07
Short % of float (12 Jan 2023) 40.76%
Short % of shares outstanding (12 Jan 2023) 40.74%
Shares short (prior month 14 Dec 2022) 41.12M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 330 Dec 2019
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 330 Dec 2019

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-110.14%
Return on equity (ttm)-229.94%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -13.74M
Net income avi to common (ttm)-13.87M
Diluted EPS (ttm)-1.4680
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)6.36M
Total cash per share (mrq)0.98
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.67
Book value per share (mrq)0.28

Cash flow statement

Operating cash flow (ttm)-12.8M
Levered free cash flow (ttm)-8.35M